Alector (ALEC)
(Delayed Data from NSDQ)
$6.49 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Alector, Inc. [ALEC]
Reports for Purchase
Showing records 1 - 20 ( 43 total )
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Eyeing the Future-Alector?s Brain Carrier (ABC) System Designed for Next Gen Neurology Drugs
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Donanemab Nears Approval - Implications for the Next Generation AD Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Top 23 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
PROGRESS-AD Rooted in Human Genetics Data Linking PGRN Levels With AD; PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Live From AD/PD Lisbon 2024-Microglia Plays a Crucial Role in Amyloid Cascade
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Secret to Being a Centenarian Without Dementia Lies with the Lysosomes - Live from AD/PD 2024 Lisbon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Plasma Biomarkers in INVOKE-2 Are Crucial to Understand AL002?s MOA
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
INFRONT-2 Data Hints of a Broader Role of PGRN in Neurodegenerative Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
AL002 is Biologically Active-Our Thoughts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Alector Pushes the Pedal on INFRONT-3, Completing Enrollment for FTD-GRN Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from CTAD 2023?Implications for the Next Generation Anti-AmyloidsThis report contains brief updates on the following: ABOS, ACIU, ALEC, BIIB, DNLI, PRTA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
AL002 Might Do More Than Removing Abeta; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Activating Microglia Might Reduce Plaque and Impact Phospho Tau Biomarkers-Thoughts on INVOKE-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
A Small Fragment of PGRN Might Be Enough to Slow Down Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
Accelerating the Pace of INFRONT-3-Our Thoughts; Reit. Buy and $41 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
TREM2 is the Most Prized Target in the Post-Lecanemab World; Reit Buy and PT $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
The Beginning of an Era of Anti-Amyloids and Combination Therapies in Alzheimer''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Alector, Inc.
Industry: Medical - Biomedical and Genetics
AL044 Reinforces Alector?s Neuroinflammation Targeting Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A